Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022
Launched by EFFIK SA · Sep 25, 2023
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Survey Purity 2022," is looking at how common nausea and vomiting are among pregnant women in Switzerland. The last study on this topic was done in 2015, and researchers want to see if new treatments for these symptoms have changed how many women experience them. To do this, they will survey pregnant women who are between 18 and 22 weeks along in their pregnancy.
To participate in the study, women need to be at least 18 years old and having a normal pregnancy—those expecting twins or who used assisted reproductive technologies won't be included. Participants will complete questionnaires in one of several languages (Italian, German, French, or English) to share their experiences with nausea and vomiting during pregnancy. The information gathered will help researchers understand how these symptoms affect women today and could lead to better support and treatments for those who suffer from them.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- Subjects will be eligible for inclusion if all the following criteria are respected:
- • Women aged ≥ 18 years.
- • Women in physiological pregnancy and between the 18th and 22nd week of pregnancy (at time of morphological ultrasound).
- • Women able to communicate adequately with the Investigator and able to read, understand and provide the answers required by the questionnaires in one of the languages in which they will be provided (Italian, German, French or English).
- • Women able to understand and who can provide valid informed consent to the Survey.
- Exclusion Criteria:
- * Subjects fulfilling one or more of the following exclusion criteria will not be included in the study:
- • Twin pregnancy.
- • Medically assisted procreation (MAP).
About Effik Sa
Effik SA is a leading pharmaceutical company specializing in the development and commercialization of innovative therapeutic solutions, particularly in the fields of reproductive health and women's health. With a strong commitment to research and development, Effik SA focuses on delivering high-quality products that address unmet medical needs. The company is dedicated to advancing clinical research through robust clinical trials, ensuring that their therapies are safe, effective, and aligned with the highest standards of regulatory compliance. By fostering collaborations with healthcare professionals and leveraging cutting-edge science, Effik SA aims to improve patient outcomes and enhance quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported